Global Multiple Sclerosis Therapeutics Industry- Market Report By Drug Class(Immunosuppressant, Immunomodulators), By Route of Administration(Oral, Injections), By Distribution Channel, By Geography, Forecast Period 2017-2025

Multiple Sclerosis Therapeutics Market Outlook, 2017-2025

The pharmaceutical industry is witnessing huge R&D activities & investments in multiple sclerosis (MS) therapeutics clinical development to target the specific disease for therapeutic administration. Due to the complex nature of MS and its unique impact on each patient has slowed down the therapeutics development process. Although there is no cure of MS but number of corticosteroids, immunosuppressant and monoclonal antibodies that reduce inflammation caused during MS, have been approved by FDA & other authorities. The hiking investments in the R&D process and rising incidence of MS diagnosed in children is driving the growth of the market. As per Goldstein Research, global multiple sclerosis therapeutics market is projected to reach market size of USD 24.9 billion by 2025, growing at a CAGR of 2.70% during the forecast period.

Our Global Multiple Sclerosis Therapeutics Market can be segmented on the following basis:

Market Segmentation

Based on Drug Class

• Immunosuppressant
• Immunomodulators

Based on the Route of Administration 

• Oral
• Injections

Based on Distribution Channel

• Healthcare Providers
• Pharmacies
  • Independent and Retail Chain
  • Mail Order Pharmacies
  • Medical Clinics
  • Online Pharmacies
  • Other Pharmacies (Speciality pharmacies, etc.)

Based on Geography 

• North America (U.S. & Canada)  Multiple Sclerosis Therapeutics Market {Market Share (%), Market Size (USD Billion)}
• Latin America (Brazil, Mexico & Rest Of Latin America)  Multiple Sclerosis Therapeutics Market {Market Share (%), Market Size (USD Billion)}
• Europe (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & Roe)  Multiple Sclerosis Therapeutics Market {Market Share (%), Market Size (USD Billion)}
• Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest Of Asia)  Multiple Sclerosis Therapeutics Market {Market Share (%), Market Size (USD Billion)}
• Middle East & Africa (GCC, South Africa, North Africa, Romea) Multiple Sclerosis Therapeutics Market {Market Share (%), Market Size (USD Billion)}

Based on drug class, immunomodulators accounted for largest market share of nearly 72.0% in 2017. Whereas, the rising R&D activities in the Immunosuppressant is witnessed to be growing at a CAGR of 15.0% over the forecast period. The presence of strong pipeline of immunosuppressant which are anticipated to get approved over the period of 4-6 years is driving the growth of the market.

Global Multiple Sclerosis Therapeutics Market Outlook comprises of the following data:

• Multiple sclerosis therapeutics market size (USD Billion) and compound annual growth rate (%), 2017-2025
• Multiple sclerosis therapeutics potential markets and major markets, 2017-2025
•  Multiple sclerosis therapeutics market drivers, challenges, growth opportunities, risk analysis, porter’s five force model and market attractiveness, 2017-2025
• Multiple sclerosis therapeutics market size (USD Billion) and compound annual growth rate (%), by drug class, 2017-2025
• Multiple sclerosis therapeutics market size (USD Billion) and compound annual growth rate (%), by route of administration, 2017-2025
• Multiple sclerosis therapeutics market size (USD Billion) and compound annual growth rate (%), by distribution channel, 2017-2025
• Multiple sclerosis therapeutic drugs under pipeline, 2016-17
• Regulatory scenario, by region
• Reimbursement Scenario, by region
• Competitors Analysis

Some of the major players included in the multiple sclerosis therapeutics market report are:

Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi Aventis, Bayer Healthcare AG, Merck, Novartis AG, AbbVie Inc.

Effectiveness of Relapsing-Remitting MS (RRMS) Oral Therapy Tecfidera:

Tecfidera was approved in 2013 by U.S. Food & Drug Administration (USFDA). It is the first line treatment of RRMS. As per Biogen, the company that is developing & commercializing Tecfidera, has announced positive results for long term benefits of the drug. Nearly 50% of people diagnosed with RRMS have experienced no relapse after the 6 years treatment of this therapy. Moreover, other MS medication alternatives such as acetate, interferon β, fingolimod, and teriflunomide haver been compared to Tecfidera and it has proved to have higher efficiency in reducing lapse rate.

Reasons to Purchase Multiple Sclerosis Therapeutics Market Report:

• Facilitate decision-making based on strong historic and forecast data
• Develop strategies based on the latest regulatory framework
• Study on the region and country that are expected to dominate the market
• Position yourself to gain the maximum advantage of the market growth potential
• Identify key partners and business development avenues across the globe
• Respond to your competitors’ business structure, strategy and visions